Liposomal Ionizable Carotenoids for Stability and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis and related conditions such as chronic endotoxemia and hypoxia are limited by the instability and low bioavailability of carotenoids, particularly crocetin and its sodium salt, which hinder their therapeutic efficacy.
Innovation Solution
Development of liposomal formulations encapsulating multivalent ionizable carotenoid salts, such as trans-crocetin and norbixin, with enhanced stability and bioavailability, to improve the pharmacokinetic properties and biodistribution of the encapsulated content, and incorporating targeting moieties for specific delivery to target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If carotenoids are administered in free form (unencapsulated), then they can be directly delivered to target sites, but their instability and low bioavailability limit therapeutic efficacy
Solution Approach 1:
The carotenoid molecules are nested within liposomal vesicles, with the hydrophobic carotenoids embedded in the liposomal lipid bilayer membrane. This nesting structure protects the carotenoids from degradation while enabling targeted delivery to hypoxic tissues through the liposomal carrier system.
Solution Approach 2:
Liposomes serve as an intermediary carrier between the carotenoid drug and the biological system. The liposomal formulation mediates the delivery by protecting carotenoids from premature degradation, improving solubility, and enabling targeted accumulation at disease sites through passive or active targeting mechanisms.
2Reliability
If carotenoids are administered in free form, then the formulation is simple, but bioavailability remains low
Solution Approach 1:
The invention changes the physical and chemical parameters of carotenoid delivery by transitioning from free form to liposomal encapsulation. This alters solubility characteristics, stability parameters, and pharmacokinetic properties, thereby significantly improving bioavailability despite increased formulation complexity.
3Adaptability or versatility
If conventional sepsis treatments are used (antimicrobials, vasopressors), then infection and hemodynamic issues are addressed, but underlying pathophysiological drivers are not treated
Solution Approach 1:
The liposomal carotenoid formulation serves multiple therapeutic functions simultaneously: it acts as an antioxidant, anti-inflammatory agent, and hypoxia-targeting therapy. This multi-functionality allows it to address underlying pathophysiological drivers of sepsis while complementing conventional treatments, thereby enhancing overall therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liposomal formulations significantly enhance the stability, bioavailability, and pharmacokinetics of carotenoids, leading to improved therapeutic outcomes in treating conditions like sepsis, ischemia, and hypoxia, with potential applications in treating a wide range of diseases and disorders.
Implementation Method 1
Carotenoids are a class of natural lipid-soluble pigments... Carotenoids are typically very lipophilic compounds... liposomes that encapsulate carotenoids
Implementation Method 2
The liposomal formulations significantly enhance the stability, bioavailability, and pharmacokinetics of carotenoids
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.